AbbVie to Acquire ImmunoGen for $10.1 Billion
November 30, 2023
AbbVie entered into a definitive agreement to acquire ImmunoGen, including its flagship ADC therapy ELAHERE (mirvetuximab soravtansine-gynx), in a deal valued at approximately $10.1 billion. The transaction is expected to close in mid-2024, subject to ImmunoGen shareholder approval, regulatory approvals, and other customary closing conditions.
- Buyers
- AbbVie Inc.
- Targets
- ImmunoGen, Inc.
- Industry
- Pharmaceuticals
- Location
- Illinois, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.